Drugs Affecting Bone Structure and Mineralization

DrugDrug NameDrug Indication
DB00169CholecalciferolCholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia [F4027, F4042]. Concurrently, as one of the most commonly utilized forms of vitamin D, cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others [A176041, A176044, F4051].
DB00282Pamidronic acidFor the treatment of moderate or severe hypercalcemia associated with malignancy
DB00399Zoledronic acidFor the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget’s Disease.
DB00630Alendronic acidAlendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
DB00710IbandronateFor the treatment and prevention of osteoporosis in postmenopausal women.
DB00720Clodronic acidFor the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
DB00884Risedronic acidRisedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis[FDA Label].
DB01077Etidronic acidFor the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
DB01133Tiludronic acidFor treatment of Paget's disease of bone (osteitis deformans).
DB01373CalciumCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades.
DB01436AlfacalcidolIndicated for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure.[label]
DB06643DenosumabProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
DB09267Strontium ranelateStrontium ranelate is therapeutically indicated for the treatment of severe osteoperosis in: a) postmenopasual women, and b) adult men, who are at high risk of fractures, for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to, for example, contraindications or intolerance. [L1127] In postmenopausal women, strontium ranelate can also reduce the risk of vertebral and hip fractures [L1127].
DB11631Eptotermin AlfaNot Available
DB11639Dibotermin alfa- indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. - indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition [L1391].
DB13618IpriflavoneNot Available
DB11573Aluminum chlorohydrateIndicated for use as an antiperspirant.
DB11866RomosozumabRomosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatments[FDA Label].
DB14012BurosumabThis drug is indicated for the treatment of X-linked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons [L2347].
DrugDrug NameTargetType
DB00169CholecalciferolVitamin D-binding proteincarrier
DB00169CholecalciferolCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB00169CholecalciferolVitamin D 25-hydroxylaseenzyme
DB00169CholecalciferolSterol 26-hydroxylase, mitochondrialenzyme
DB00169CholecalciferolCytochrome P450 2J2enzyme
DB00169CholecalciferolCytochrome P450 3A4enzyme
DB00169CholecalciferolVitamin D3 receptortarget
DB00169CholecalciferolCytochrome P450 1A1enzyme
DB00169CholecalciferolCytochrome P450 2B6enzyme
DB00169CholecalciferolCytochrome P450 2C8enzyme
DB00169CholecalciferolCytochrome P450 2D6enzyme
DB00282Pamidronic acidFarnesyl pyrophosphate synthasetarget
DB00282Pamidronic acidHydroxylapatitetarget
DB00399Zoledronic acidFarnesyl pyrophosphate synthasetarget
DB00399Zoledronic acidGeranylgeranyl pyrophosphate synthasetarget
DB00399Zoledronic acidHydroxylapatitetarget
DB00399Zoledronic acidMultidrug resistance-associated protein 1transporter
DB00630Alendronic acidFarnesyl pyrophosphate synthasetarget
DB00630Alendronic acidTyrosine-protein phosphatase non-receptor type 4target
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase Starget
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase epsilontarget
DB00630Alendronic acidV-type proton ATPase catalytic subunit Atarget
DB00630Alendronic acidHydroxylapatitetarget
DB00710IbandronateFarnesyl pyrophosphate synthasetarget
DB00720Clodronic acidADP/ATP translocase 2target
DB00720Clodronic acidADP/ATP translocase 1target
DB00720Clodronic acidADP/ATP translocase 3target
DB00720Clodronic acidHydroxylapatitetarget
DB00720Clodronic acidProstaglandin G/H synthase 2enzyme
DB00884Risedronic acidFarnesyl pyrophosphate synthasetarget
DB00884Risedronic acidHydroxylapatitetarget
DB00884Risedronic acidProstaglandin G/H synthase 2enzyme
DB01077Etidronic acidHydroxylapatitetarget
DB01077Etidronic acidReceptor-type tyrosine-protein phosphatase Starget
DB01077Etidronic acidV-type proton ATPase catalytic subunit Atarget
DB01077Etidronic acidAdenosine triphosphate (ATP)target
DB01133Tiludronic acidTyrosine-protein phosphatase non-receptor type 1target
DB01133Tiludronic acidV-type proton ATPase catalytic subunit Atarget
DB01133Tiludronic acidHydroxylapatitetarget
DB01133Tiludronic acidAdenosine triphosphate (ATP)target
DB01373CalciumProtein S100-Btarget
DB01373CalciumCartilage oligomeric matrix proteintarget
DB01373CalciumSpectrin beta chain, non-erythrocytic 1target
DB01373CalciumVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01373CalciumTroponin C, skeletal muscletarget
DB01373CalciumTroponin C, slow skeletal and cardiac musclestarget
DB01373CalciumCalcium-transporting ATPase type 2C member 1target
DB01373CalciumAmiloride-sensitive amine oxidase [copper-containing]target
DB01373CalciumProtein S100-A13target
DB01373CalciumAlkaline phosphatase, placental typetarget
DB01373CalciumProtein S100-A8target
DB01373CalciumProtein S100-A9target
DB01373CalciumProtein S100-A2target
DB01373CalciumBone morphogenetic protein 4target
DB01373CalciumMatrix Gla proteintarget
DB01373CalciumProgrammed cell death protein 6target
DB01436AlfacalcidolVitamin D-binding proteincarrier
DB01436AlfacalcidolVitamin D3 receptortarget
DB01436Alfacalcidol25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialtarget
DB01436AlfacalcidolRetinoic acid receptor RXR-alphatarget
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB11639Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
DB11639Dibotermin alfaBone morphogenetic protein receptor type-2target
DB14012BurosumabFibroblast growth factor 23target